title: Anti-IgE--emerging opportunities for Omalizumab.
abstract: BACKGROUND
  Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to free and membrane-bound immunoglobulin E (IgE) antibodies. Omalizumab has been licensed for use in severe allergic asthma. A search on the website clinicaltrials.gov reveals there are currently 109 clinical trials with Omalizumab of which 46 are for conditions other than asthma.
  
  
  METHODS
  In addition to asthma, Omalizumab has been investigated in various other conditions including perennial and seasonal allergic rhinitis (AR), peanut allergy, latex allergy, atopic dermatitis, chronic urticaria (CU), idiopathic anaphylaxis, mastocytosis, eosinophilic gastroenteritis and nasal polyposis. This review aims to look at the various randomised and non-randomised clinical trials, case series and case reports for the role of Omalizumab in conditions other than asthma. Numerous clinical trials have shown a positive light on the role of Omalizumab in conditions other than asthma.
  
  
  CONCLUSIONS
  We feel that the future of Omalizumab would include a more diverse range of clinical conditions, and future trials should not only look into the clinical usefulness but also the economic impact of using this interesting molecule.
authors.affiliation: Queen Alexandra Hospital, Respiratory Medicine, Level C, Southwick Hill Road, Cosham, Portsmouth, PO6 3LY, UK. sureshbabu97@gmail.com
authors.forename: K Suresh
authors.initials: KS
authors.lastname: Babu
authors.forename: Riccardo
authors.initials: R
authors.lastname: Polosa
authors.forename: Jaymin B
authors.initials: JB
authors.lastname: Morjaria
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D005512:Food Hypersensitivity / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000502:physiology*; D007167:Immunotherapy / Q000379:methods; D000069444:Omalizumab; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D014862:Wasp Venoms / Q000276:immunology
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D014862:Wasp Venoms; D000069444:Omalizumab; D007073:Immunoglobulin E